Vesper Ventures

Inedita Bio is engaged in the development of a plant genome editing platform designed to promote sustainable food production. The company focuses on creating non-transgenic, genome-edited crop varieties that enhance resistance to pests and diseases, while also improving water and nutrient use efficiency. By making precise modifications to the genetic code of plants, Inedita Bio aims to recover lost variability that conventional breeding techniques may have diminished. This innovative approach not only reduces dependence on chemical pesticides but also supports environmentally friendly agricultural practices, contributing to the overall sustainability of food production.

Vyro Bio is a biotechnology company focused on immuno-oncology, specifically developing oncolytic viruses aimed at treating both adult and pediatric central nervous system tumors. The company leverages pioneering research into the oncolytic properties of the Zika Virus to create therapies that effectively target aggressive and fast-growing brain tumors. Through its innovative approach, Vyro Bio seeks to provide healthcare professionals with new treatment options for patients suffering from these challenging cancers.

Aptah specializes in drug design through an innovative algorithm that accelerates the drug discovery process. By streamlining lead optimization and customization, Aptah significantly reduces the time, cost, and risks typically associated with developing new drugs. The company has successfully created new molecules aimed at treating cancer, anti-inflammatory conditions, and developing oligonucleotides for gene therapy. Aptah's method replaces traditional techniques, such as the SELEX process, with a more efficient approach that allows for rapid identification of effective drug candidates within days. This advancement not only enhances the precision of drug discovery but also makes it more accessible to medical professionals, ultimately improving the availability of novel therapies for various diseases, including cancer and neurodegenerative disorders.